Bronchogenic carcinoma complicating lung transplantation

Arcasoy, Selim M.; Hersh, Craig P.; Christie, Jason D.; Zisman, David A.; Pochettino, Alberto; Rosengard, Bruce R.; Blumenthal, Nancy P.; Palevsky, Harold I.; Bavaria, Joseph E.; Kotloff, Robert M.

doi:10.1016/s1053-2498(01)00301-1

Cited by 71 publications

(62 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior studies have reported the frequency of post-transplant bronchogenic carcinoma to range from 0% to 2.5% in SLTx recipients and to be 0% in BLTx recipients. [1][2][3][4][5] Our higher frequency of malignancy is likely explained in part by the longer-term follow-up in our study as compared with prior studies. In our cohort we included patients surviving >90 days post-transplant and who had a mean of >5 years post-transplant follow-up.…”

Section: Discussionmentioning

confidence: 49%

“…7 The mean age of our study population (55.4 years) was older than that reported in prior studies (44 to 51 years; overall mean 46.9 years); similarly, the percentage of our patients who received transplantation for COPD (75%) far exceeded the range reported in past studies (32% to 56%). [1][2][3][4][5] As our study demonstrated that increasing age and smoking history are risk factors for the development of primary post-transplant lung cancer, it is not surprising that these demographic trends would be accompanied by an increased frequency of lung cancer in this population.…”

Section: Discussionmentioning

confidence: 62%

See 1 more Smart Citation

High Frequency of Bronchogenic Carcinoma After Single-lung Transplantation

Dickson

Davis

Rea

et al. 2006

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Background-Lung transplantation is a commonly employed therapy in the treatment of patients with advanced lung diseases related to tobacco use. Little is known about the long-term incidence or risk factors for primary lung cancer after lung transplantation. To determine the frequency, clinical features and risk factors for primary bronchogenic malignancy after lung transplantation, we designed a matched cohort study of single and bilateral lung transplant recipients with extended follow-up.

show abstract

Section: Discussionmentioning

confidence: 49%

Section: Discussionmentioning

confidence: 62%

High Frequency of Bronchogenic Carcinoma After Single-lung Transplantation

Dickson

Davis

Rea

et al. 2006

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

show abstract

“…Nevertheless patients with unforeseen stage I bronchial carcinoma discovered in the explanted lung during actual transplantation may survive without recurrence for many years comparable to recipients transplanted for other diagnoses. Patients with more advanced disease, however, will do poorly after lung transplantation as they have a high chance to develop recurrences and to die within 1 year with widespread metastases (22,(28)(29)(30)(31)(32)(33)(34).…”

Section: Primary Lung Cancermentioning

confidence: 99%

Lung cancer: a rare indication for, but frequent complication after lung transplantation

Raemdonck¹,

Vos²,

Yserbyt³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Lung transplantation is an effective and safe therapy for carefully selected patients suffering from a variety of end-stage pulmonary diseases. Lung cancer negatively affects prognosis, particularly in patients who are no longer candidates for complete resection. Lung transplantation can be considered for carefully selected and well staged lung cancer patients with proven, lung-limited, multifocal, (minimally invasive) adenocarcinoma in situ (AIS) (previously called bronchioloalveolar cell carcinoma) causing respiratory failure. Despite a substantial risk of tumour recurrence (33-75%), lung transplantation may offer a survival benefit (50% at 5 years) with best palliation of their disease. Reports on lung transplantation for other low-grade malignancies are rare. Lung transplant candidates at higher risk for developing lung cancer [mainly previous smokers with chronic obstructive lung disease (COPD) and idiopathic pulmonary fibrosis (IPF) or older patients] should be thoroughly and repeatedly screened for lung cancer prior to listing, and preferably also during waiting list time if longer than 1 year, including the use of PET-CT scan and EBUS-assisted bronchoscopy in case of undefined, but suspicious pulmonary abnormalities. Double-lung transplantation should now replace single-lung transplantation in these high-risk patients because of a 6-9% prevalence of lung cancer developing in the remaining native lung. Patients with unexpected, early stage bronchial carcinoma in the explanted lung may have favourable survival without recurrence. Early PET-CT (at 3-6 months) following lung transplantation is advisable to detect early, subclinical disease progression. Donor lungs from (former) smokers should be well examined at retrieval. Suspicious nodules should be biopsied to avoid grafting cancer in the recipient. Close follow-up with regular visits and screening test in all recipients is needed because of the increased risk of developing a primary or secondary cancer in the allograft from either donor or recipient origin.

show abstract

“…Additionally, the majority of these patients have significant smoking histories. The reported incidence of lung cancer following transplantation is 2.0-3.7% in patients with chronic obstructive lung disease and 3.4-4.0% for the pulmonary fibrosis population [44,45]. Data are conflicting on whether transplantation confers an increased likelihood of developing this form of cancer or whether the incidence is comparable with that of the general population with similar risk factors [46].…”

Section: Lung Cancermentioning

confidence: 99%

“…Lung cancer may complicate the transplant course in several ways. Previously unsuspected cancer may be incidentally detected in the explanted lung at the time of transplantation, placing the recipient at risk for subsequent recurrence [44]. On occasion, LTx has been performed as definitive treatment for underlying bronchoalveolar carcinoma; a high rate of recurrence in the allografts has been documented in these circumstances [47].…”

Section: Lung Cancermentioning

confidence: 99%

Medical complications of lung transplantation

Kotloff¹,

Ahya²

2004

Eur Respir J

View full text Add to dashboard Cite

Many of the medical complications that arise are the direct consequence of the need to administer potent immunosuppressive agents, with their attendant risks of infection, malignancy and drug toxicity.This article will review the major medical complications, excluding allograft rejection, which may be encountered in the lung transplant recipient. Familiarity with, and vigilance for, these problems should facilitate earlier recognition, more expeditious intervention and more favourable outcomes. Eur Respir J 2004; 23: 334-342. Pulmonary, Allergy, and Critical Care Division,

show abstract

Bronchogenic carcinoma complicating lung transplantation

Cited by 71 publications

References 20 publications

High Frequency of Bronchogenic Carcinoma After Single-lung Transplantation

High Frequency of Bronchogenic Carcinoma After Single-lung Transplantation

Lung cancer: a rare indication for, but frequent complication after lung transplantation

Medical complications of lung transplantation

Contact Info

Product

Resources

About